Loblaw's Earnings Are Fair. Its 29x Multiple Looks Expensive.

Fair value looks well below the current price

Loblaw looks expensive relative to the latest fundamental picture. After last week's quarterly report, shares fell 4.0% to CA$60.10 even though results were roughly in line with estimates. The business did not suddenly worsen; what changed is that investors had a fresh reason to question whether the stock was already priced for more than the operating update justified.

Fair profits, expensive price

A fair-value estimate based on the latest evidence sits near CA$50.74, while the stock was trading around CA$61.50. Using a later community snapshot, the price was still near CA$62.29. That suggests the stock may be trading ahead of fair value, with valuation doing more of the heavy lifting than current fundamentals.

That view is not based on weak results. Simply Wall St noted the latest forecasts still point to CA$65.6b of 2026 revenue and CA$2.27 EPS, broadly in line with recent expectations. For a retailer with only a modest forecast upgrade, that can still look rich if investors keep paying a premium multiple.

Why investors still pay Loblaw a premium

The valuation gap explains how expensive Loblaw looks. It does not explain why the market keeps lending it a richer multiple.

Loblaw has real operating strength

Loblaw's quality is not imaginary. In the fourth quarter, the company delivered adjusted diluted EPS growth of 10.9% on a 12-week comparable basis while gross profit percentage improved by 10 basis points. Management also said customer visits increased and that it continued to gain share across its banners. That is the profile of a retailer with better scale, merchandising discipline, and shopper loyalty than many peers.

There is also a structural reason investors lean toward Loblaw. It is described as the largest food and drug seller in Canada, with dominant-player status and strong economies of scale. In a sector under pressure from public anger over grocery pricing, that scale can make the company look more resilient than weaker competitors.

Where operating quality can become overpayment

The bull case is straightforward: Loblaw may deserve a premium because its format mix, private-label strength, and pharmacy footprint can make it more resilient than the average retailer.

But strong execution is not the same as a new growth inflection. Post-earnings, the Street is still looking for roughly CA$65.6b of 2026 revenue and CA$2.27 EPS, only modestly better than prior expectations. That supports a careful interpretation: Loblaw may deserve confidence, but not automatically unlimited multiple expansion.

What could pressure the premium

The premium does not need a scandal to compress. It only needs another quarter of good-enough performance when the stock is already trading above where fundamentals point. Last week's reaction was the clearest warning: shares fell 4.0% to CA$60.10 even though results were roughly in line with estimates. That does not signal a fundamental break. It does suggest investors are becoming more valuation-sensitive.

What investors should watch next

The main risk is not poor execution by itself. It is steady execution without a meaningfully stronger forward story. After last week's report, estimate changes remained muted. At the same time, published sentiment has stayed positive, including a Top Pick view from one analyst source. If optimism stays high while forward estimates barely move, the stock becomes more vulnerable to a valuation reset.

The most useful signals over the next few updates are: - whether revenue growth holds above the Q4 3.5% level; - whether adjusted diluted EPS growth stays around or above 10.9% on a 12-week comparable basis; - whether guidance becomes firmer; - and whether margins remain stable enough to support the current multiple.

If Loblaw can build from that base, the premium can hold. If updates remain merely solid, the market may keep concluding that quality alone is not enough to justify the price.